TOP PAPERS in MEDICAL MYCOLOGY Laboratory Diagnosis Manuel Cuenca-Estrella Abril 2018

Similar documents
Top 5 papers in clinical mycology

ECMM Excellence Centers Quality Audit

Is pre-emptive therapy a realistic approach?

WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?

Terapia della candidiasi addomaniale

TIMM 2013 Role of non-culture biomarkers for detection of fungal infections

Invasive Pulmonary Aspergillosis in

Reducing the antifungal drugs consumption in the ICU

Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences

Fungal Infection in the ICU: Current Controversies

TOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR

Dr Eggimann collaborated in several industrysponsored. clinical trials since Talk ID: year old BMI 41 Transferred for septic shock

Received 6 October 2010/Returned for modification 26 December 2010/Accepted 7 January 2011

Objec&ves. Clinical Presenta&on

ADVANCES AND CHALLENGES IN HEMATOLOGY. Invasive fungal disease management in febrile neutropenia

Research priorities in medical mycology

Outline NEW DIAGNOSTIC TOOLS WHY? WHICH TESTS? WHEN TO USE THEM? Documented IFI

Antifungal Stewardship. Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul

Antifungals and current treatment guidelines in pediatrics and neonatology

The EMPIRICUS trial the final nail in the coffin of empirical antifungal therapy in the intensive care unit?

An Update in the Management of Candidiasis

Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside

Solid organ transplant patients

INFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU. Claudio Viscoli Professor of Infectious Disease University of Genoa

Controversies in management: prophylaxis or diagnostics

Risk Factors for IFI Length of ICU stay. Fungal Biomarkers

Aspergillosis in the critically ill patient

WHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU?

New Directions in Invasive Fungal Disease: Therapeutic Considerations

I am against to TDM in critically ill patient

New insights in the diagnosis of Candida infections

Candidemia: Lessons learnt from Asian studies for intervention

Fungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia

ESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel

MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS

PAGL Inclusion Approved at January 2017 PGC

Micafungin, a new Echinocandin: Pediatric Development

Received 1 December 2009/Accepted 26 January 2010

Data Mining Validation of Fluconazole Breakpoints Established by the European Committee on Antimicrobial Susceptibility Testing

PROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino

Prevention and management of antifungal-resistant infections in the ICU

How to make a fast diagnosis

Clinical Performance of the (1,3)- -D-Glucan Assay in Early Diagnosis of Nosocomial Candida Bloodstream Infections

Aspergillosis in Pediatric Patients

Update on Antifungal Stewardship

Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units

ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST

La terapia empirica nelle infezioni micotiche

Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013

Nijmegen Institute for Infection, Inflammation and Immunity (N4i) 2, Nijmegen, the. and Hematology 4, University Medical Center

Supplementary Materials to the Manuscript: Polymorphisms in TNF-α Increase Susceptibility to

No Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany

Ventilator Associated Pneumonia. ICU Fellowship Training Radboudumc

1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans

Antifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary

Systemic Candidiasis for the clinicians: between guidelines and daily clinical practice

Resistance epidemiology

Invasive Mycoses: Diagnostic Challenges

Broad spectrum triazoles: which drug and when?

ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS

The goal of teaching:

Difficult to diagnose fungal infections: Non-fungaemic candidiasis

Invasive Fungal Infections in Critically Ill Patients. Dr Ravinder Kaur Director Professor&HOD Department of Microbiology,LHMC

ESCMID Online Lecture Library. by author

Use of Antifungals in the Year 2008

Effect of reduced oxygen on the antifungal susceptibility of clinically relevant

Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies

Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong

Case Studies in Fungal Infections and Antifungal Therapy

FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia

Indre Vengalyte MD¹, Regina Pileckyte MD¹, Laimonas Griskevicius MD PhD 1, 2

Dutch Working Party on Antibiotic Policy. SWAB Guidelines for the Management of Invasive Fungal Infections

Approach to Fungal Infections

Management and diagnostic guidelines for fungal diseases in infectious diseases and clinical microbiology: critical appraisal

Antimykotische Therapie und TDM: ECIL 6 Guidelines

Common Fungi. Catherine Diamond MD MPH

Early treatment of candidemia in adults: a review

Antimykotische Therapie und TDM: ECIL 6 Guidelines

Antifungal Susceptibility of Aspergillus Isolates from the Respiratory Tract of Patients in Canadian Hospitals: Results of the CANWARD 2016 Study.

8/24/2015. Objectives (Pharmacists) Azoles: Mechanism of action. Objectives (Technicians)

Therapeutic Options: Where do we stand? Where do we go?

CD101: A Novel Echinocandin

TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY

FUNGAL INFECTIONS IN THE MIDDLE EAST NEWSLETTER

Impact of the revised (2008) EORTC/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis

Fungal (Aspergillus and Candida) infections in Cystic fibrosis

Mycology Reference Centre, Leeds Information for Service Users 2017

When is failure failure?

Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures

Management Strategies For Invasive Mycoses: An MD Anderson Perspective

Early Diagnosis and Therapy for Fungal Infections

Fungal infections in the ICU: advances in treatment and diagnosis

Antifungal Pharmacodynamics A Strategy to Optimize Efficacy

Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients

Fungal infection in the immunocompromised patient. Dr Kirsty Dodgson

Early Presumptive Therapy EPT

2046: Fungal Infection Pre-Infusion Data

Fungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA

Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis

Clinical relevance of resistance in Aspergillus. David W. Denning University Hospital of South Manchester [Wythenshawe Hospital]

Transcription:

TOP PAPERS in MEDICAL MYCOLOGY Laboratory Diagnosis Manuel Cuenca-Estrella Abril 2018 MCE01

Conflict of interest disclosure In the past 5 years, M.C.E. has received grant support from Astellas Pharma, biomerieux, Gilead Sciences, Merck Sharp and Dohme, Pfizer, Schering Plough, Soria Melguizo SA, Ferrer International He has been an advisor/consultant to the Panamerican Health Organization, Astellas Pharma, Gilead Sciences, Merck Sharp and Dohme, Pfizer, and Schering Plough He has been paid for talks on behalf of Gilead Sciences, Merck Sharp and Dohme, Pfizer, Astellas Pharma and Schering Plough MCE02

Top Papers in Medical Mycology Diagnostic Topics (April 2017 to April 2018) 800 (approx.) references on PubMed website My review criteria: Diagnostic Relevance Technical Novelty Strength of evidences Recommendations by colleagues

Top Papers in Medical Mycology Diagnostic Topics (April 2017 to April 2018) Diagnosis of invasive candidiasis (IC) and candidemia Diagnosis of invasive pulmonary aspergillosis (IPA) Antifungal resistance detection Therapeutic drug monitoring (TDM) Other topics

Diagnosis of invasive candidiasis (IC) and candidemia

Candida infections in the Intensive Care setting As many as 65% of Intensive Care patients are treated empirically (no positive cultures) with antifungal agents Azoulay et al. Crit Care Med 2012;40:813 22 MCE03

Candida infections in the Intensive Care setting Scores or rules to treat correctly: Ostrosky-Zeichner score 1 Candida score 2 Colonization index 3 Candida score: 3 points: treatment after 7 d at intensive care units Sepsis Colonization Abdominal surgery Parenteral nutrition Positive Predictive Value: 14% 2 1. Ostrosky-Zeichner et al. Mycoses 2011;54:46 51 2. León et al. Crit Care Med 2009;37:1624 33 3. Pittet et al. Ann Surg 1994;220:751 8 MCE04

Colombo AL et al. Lancet Infect Dis 2017;17:e344 56

A total of 152 patients with Candida positive blood cultures T2 clinical sensitivity was 89% Clancy et al. Clin Infect Dis 2018

Mylonakis et al. J Clin Microbiol2018;56:e01756-17

Muñoz et al. J Antimicrob Chemother 2018;73 Suppl 4:iv13-19

Ramos JT et al. J Clin Microbiol. 2017;55:2752-64

110 ICU patients with high risk of invasive candidiasis. Symptoms and empirical therapy Two groups: 1. Beta-D-Glucan and mannan and antimannan quantification and therapy was discontinued if negative biomarkers 2. Standard of care, 14 days of antifungal therapy Antifungal therapy was discontinued in 29/54 patients in the biomarker group and 1/55 in the standard of care group No significant difference was found in patients with subsequent proven invasive Candida infection, mechanical ventilation-free days, length of ICU stay, cost, and ICU mortality between the two study groups Rouzhe A et al. Inten Care Med. 2017;43:1668-77

Chowdhary A et al. Plos Pathogenns. 2017;13:e1006290

Kohlenberg A et al. Eurosurveillance. 2018;23:9/03/2018

Chowdhary A et al. J Antimicrob Chemother. 2018;73:891-9

Diagnosis of invasive pulmonary aspergillosis (IPA)

Aspergillus infections: What we know Galactomannan (GM) detection shows a good performance to rule out the infection in neutropenic patients PCR-based techniques, beta-d-glucan detection (BDG) and lateral flow devices seem to have a lower performance Combination of techniques could be the best strategy to detect the infection, much better in respiratory samples ESCMID Aspergillus Guidelines. Clin Microbiol Infect 2018;In press MCE03

ESCMID-ECMM-ERS Aspergillus Guidelines. Clin Microbiol Infect 2018;In press

Eigl et al. Med Mycol. 2017; 55:528-34

Taghizadeh-Armaki M et al. J Med Microbiol. 2017; 66:898-904

Signature of alveolar cytokines could be associated with the development of IPA and used as a diagnostic biomarker Case-control study, 113 patients (57 cases of IPA) IL-1b, IL-6, IL-8, IL-17A, IL-23, and TNFa were significantly increased among patients with IPA IL-8 was the best performing cytokine, with alveolar levels 904 pg/ml predicting IPA with elevated sensitivity (90%), specificity (73%), and negative predictive value (88%) Goncalves SM et al. Front Microbiol. 2017; 8:2362

Van de Veerdonk FL et al. Nature Rev. 2017; 15:661-74

Evaluation of performance in sputum of GM compared to PCR-based method to detect chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA) 159 patients. 223 sputum sample pairs were retrospectively analysed A GM index of 6.5 was associated with approximately 50% of strongly positive PCR values GM quantification is not reliable for detection of those clinical entities

370 cases from 21 countries. 5% of clinical samples positive for moulds. AMB median MIC: 8 mg/l Risslegger B et al. Clin Microbiol Infect. 2017; 23:776e1-e5

Antifungal Resistance Detection

Perlin DS et al. Lancet Infect Dis 2017; 17:e383-92

García-Rubio R et al. Drugs 2017; 77:599-613

Haematological patients, 432 high risk cases for IPA 36 cases (8.3%) of probable and proven IPA 2/36 cases (5.5%) triazole resistance Low rate of resistance in patients with IPA but it could be underestimated. Vigilance needed Lestrade et al. J Antimicrob Chemother. 2018;

Perlin DS et al. Lancet Infect Dis 2017; 17:e383-92

Multicenter study. 2,018 Candida isolates Rezafungin showed species-specific activity in vitro similar to other echinocandins Resistance in vitro is scantly detected Further studies warranted to set breakpoints Arendrup MC et al. Clin Microbiol Infect 2018

Therapeutic Drug Monitoring

Therapeutic Drug Monitoring (TDM) ESCMID-ECMM-ERS Aspergillus Guidelines. Clin Microbiol Infect 2018;In press

Other Topics

Temfack E et al. Front Microbiol 2018;9:409 Detection of serum cryptococcal antigen (Ag) predicts development of meningitis in HIV-infected patients with severe immune depression. Pre-emptive oral fluconazole is thus recommended. A semi-quantitative Ag screening approach could offer clinically relevant advantages

Lactate dehydrogenase may be elevated Computed tomography scans of the chest are bilateral groundglass opacities with or without cystic lesions Bronchoalveolar lavage shows better diagnostic yield compared to induced sputum. Immunofluorescence has higher performance than conventional staining Combination of different diagnostic tests such as microscopy, PCR-based methods, and beta-d-glucan detection could be the standard of care Salzer HJF et al. Respiration 2018;

40 cases evaluated Dantas KC et al. PLOS One 2018;13:e0190408

Availability of MLP (Microsatellite Length Polymorphism) and MLST (Multilocus Sequence Analysis) to analyze infection chain, outbreaks and hospital transmission Alanio A et al. Clin Microbiol Rev 2017;30:671-707

Alanio A et al. EBioMedicine 2017;22:155-67

Chindamporn A. et al. Med Mycol. 2017.0:1-10

Laboratory techniques (241 Asian centers, 7 countries) Independent Mycology Laboratory % Diagnostic Service Availability Antifungal susceptibility testing 59% Comments 53% Accredited <50% >90% reference methods Therapeutic Drug Monitoring 38% 50% HPLC Galactomannan quantification 23% 47% 2 days/week Beta-D-Glucan determination 10% 30% have Candida mannans PCR-based tests 38% 70% In-house tests HPLC: High Pressure Liquid Chromatography Chindamporn A. et al. Med Mycol. 2017.0:1-10

Conclusions The ESCMID-ECMM-ERS Aspergillus Guidelines is probably the 2018 Top Paper in Laboratory Mycology The biomarkers can be useful into therapeutic algorithms on invasive candidiasis. The T2MR test is an interesting novelty The GM quantification in bronchoalveolar lavage in combination with PCR could become the diagnostic standard of care of invasive pulmonary aspergillosis (same biomarker-based strategy for other IFDs)